Baird analyst Brian Skorney downgraded Applied Therapeutics (APLT) to Neutral from Outperform with a price target of 25c, down from $2, after Applied agreed to be acquired by Cycle Group for 8.8c per share in cash payable at closing plus one non-transferrable contingent value right that entitles the holder to receive potential additional payments.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLT: